Blog

Take Two and Call Me In the Morning: OEHHA Publishes Proposition 65 Hazard Identification Document for Acetominophen

In announcing the December 5, 2019 meeting of the Proposition 65 Cancer Identification Committee (CIC), OEHHA has published its Hazard Identification Document for acetominophen. Publication of the HID begins the public comment period on the document; the deadline for comments is November 4, 2019. Members of the public also may provide oral comments at the meeting.

Acetominophen is a widely used analgesic and antipyretic drug which first became available without a prescription in 1955. The HID, over 350 pages long, evaluates and summarizes a number of studies relating to this OTC drug. At the upcoming CIC meeting, committee members will discuss, and ultimately vote on, whether acetominophen should be added to the Proposition 65 list as a carcinogen.

If acetominophen is added to the list, the Proposition 65 warning requirement will become effective one year later. Manufacturers and sellers of this OTC drug then will surely need some of that pain relief.

Grimaldi Law Offices has been advising clients for over 20 years on chemical and product regulation. For knowledgeable advice and in-depth analysis on your chemical regulatory compliance obligations, contact Grimaldi Law Offices at (415) 463-5186 or email us at [email protected].

This is attorney advertising.

Ms. Grimaldi maintains a diverse environmental law practice focusing on chemical and product regulation and litigation defense. Her practice areas include Proposition 65, California's Safer Consumer Products Regulations, California's Rigid Plastic Packaging Container Act and the federal Toxic Substances Control Act. Ms. Grimaldi graduated from the University of California Hastings College of the Law magna cum laude and holds a Bachelor of Science Degree in Bacteriology from University of California, Davis. Prior to attending law school, she worked as a research assistant in laboratories at the University of California, San Francisco Cancer Research Institute and at the University of California, San Francisco School of Medicine.